These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 38496700)

  • 21. Targeting DNA damage response pathways in cancer.
    Groelly FJ; Fawkes M; Dagg RA; Blackford AN; Tarsounas M
    Nat Rev Cancer; 2023 Feb; 23(2):78-94. PubMed ID: 36471053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors.
    Clark CA; Yang ES
    J Immunother Precis Oncol; 2023 Feb; 6(1):31-49. PubMed ID: 36751656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA damage response inhibitors: An avenue for TNBC treatment.
    Jin J; Tao Z; Cao J; Li T; Hu X
    Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188521. PubMed ID: 33556453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
    Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
    Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer.
    Khaddour K; Felipe Fernandez M; Khabibov M; Garifullin A; Dressler D; Topchu I; Patel JD; Weinberg F; Boumber Y
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel DNA damage repair-related signature for predicting prognositc and treatment response in non-small lung cancer.
    Li L; Zou BJ; Zhao JZ; Liang JB; She ZY; Zhou WY; Lin SX; Tian L; Luo WJ; He FZ
    Front Oncol; 2022; 12():961274. PubMed ID: 36408135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
    Aktas BY; Guner G; Guven DC; Arslan C; Dizdar O
    Expert Rev Anticancer Ther; 2019 Jul; 19(7):589-601. PubMed ID: 31181965
    [No Abstract]   [Full Text] [Related]  

  • 29. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.
    Maresca L; Stecca B; Carrassa L
    Cells; 2022 Apr; 11(9):. PubMed ID: 35563772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting DNA damage response as a potential therapeutic strategy for head and neck squamous cell carcinoma.
    Lei H; He A; Jiang Y; Ruan M; Han N
    Front Oncol; 2022; 12():1031944. PubMed ID: 36338767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA damage response pathways in tumor suppression and cancer treatment.
    Liang Y; Lin SY; Brunicardi FC; Goss J; Li K
    World J Surg; 2009 Apr; 33(4):661-6. PubMed ID: 19034564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities.
    Jurkovicova D; Neophytou CM; Gašparović AČ; Gonçalves AC
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.
    Carrassa L; Colombo I; Damia G; Bertoni F
    Cancer Treat Rev; 2020 Nov; 90():102090. PubMed ID: 32892059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
    J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA mutations in pancreatic cancer and progress in their targeting.
    Alkassis S; Yazdanpanah O; Philip PA
    Expert Opin Ther Targets; 2021 Jul; 25(7):547-557. PubMed ID: 34289788
    [No Abstract]   [Full Text] [Related]  

  • 38. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study.
    Xiao Z; Sun L; Zheng Y; Chen H; Zheng X; Luo J; Gu C; Lin R; Huang M; Bai Y; Chen ZS; Kinslow CJ; Loh J; Lin L
    Transl Lung Cancer Res; 2022 Dec; 11(12):2539-2566. PubMed ID: 36636408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting DNA repair mechanisms in cancer.
    Furgason JM; Bahassi el M
    Pharmacol Ther; 2013 Mar; 137(3):298-308. PubMed ID: 23107892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.